Obesity and Metabolism Laboratory, Institute for Drug Research, School of Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem 9112001, Israel.
Obesity and Metabolism Laboratory, Institute for Drug Research, School of Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem 9112001, Israel.
Eur J Intern Med. 2018 Mar;49:23-29. doi: 10.1016/j.ejim.2018.01.009. Epub 2018 Jan 11.
Endocannabinoids (eCBs) are internal lipid mediators recognized by the cannabinoid-1 and -2 receptors (CBR and CBR, respectively), which also mediate the different physiological effects of marijuana. The endocannabinoid system, consisting of eCBs, their receptors, and the enzymes involved in their biosynthesis and degradation, is present in a vast number of peripheral organs. In this review we describe the role of the eCB/CBR system in modulating the metabolism in several peripheral organs. We assess how eCBs, via activating the CBR, contribute to obesity and regulate food intake. In addition, we describe their roles in modulating liver and kidney functions, as well as bone remodeling and mass. Special importance is given to emphasizing the efficacy of the recently developed peripherally restricted CBR antagonists, which were pre-clinically tested in the management of energy homeostasis, and in ameliorating both obesity- and diabetes-induced metabolic complications.
内源性大麻素（eCBs）是被大麻素-1 和 -2 受体（CBR 和 CBR，分别）识别的内脂质介质，它们也介导大麻的不同生理效应。由 eCBs、其受体以及参与其生物合成和降解的酶组成的内源性大麻素系统存在于大量的外周器官中。在这篇综述中，我们描述了 eCB/CBR 系统在外周多个器官代谢调节中的作用。我们评估了 eCBs 通过激活 CBR 如何导致肥胖和调节食物摄入。此外，我们还描述了它们在调节肝、肾功能以及骨重塑和质量中的作用。特别强调了最近开发的、在能量平衡管理以及改善肥胖和糖尿病引起的代谢并发症的临床前测试中显示出疗效的外周受限 CBR 拮抗剂的重要性。
